Cargando…

Study partners should be required in preclinical Alzheimer’s disease trials

BACKGROUND: In an effort to intervene earlier in Alzheimer’s disease (AD), clinical trials are testing promising candidate therapies in preclinical disease. Preclinical AD trial participants are cognitively normal, functionally independent, and autonomous decision-makers. Yet, like AD dementia trial...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grill, Joshua D., Karlawish, Jason
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5719524/ https://www.ncbi.nlm.nih.gov/pubmed/29212555 http://dx.doi.org/10.1186/s13195-017-0327-x

Ejemplares similares

Study partners: essential collaborators in discovering treatments for Alzheimer’s disease
por: Largent, Emily A., et al.
Publicado: (2018)

Addressing the challenges to successful recruitment and retention in Alzheimer's disease clinical trials
por: Grill, Joshua D, et al.
Publicado: (2010)

Reactions to learning a “not elevated” amyloid PET result in a preclinical Alzheimer’s disease trial
por: Grill, Joshua D., et al.
Publicado: (2018)

African Americans are less likely to enroll in preclinical Alzheimer's disease clinical trials
por: Zhou, Yan, et al.
Publicado: (2016)

Study partner types and prediction of cognitive performance: implications to preclinical Alzheimer’s trials
por: Nuño, Michelle M., et al.
Publicado: (2019)

Participant and study partner prediction and identification of cognitive impairment in preclinical Alzheimer’s disease: study partner vs. participant accuracy
por: Ryan, Mary M., et al.
Publicado: (2019)

Recruiting to preclinical Alzheimer's disease clinical trials through registries
por: Grill, Joshua D.
Publicado: (2017)

Preclinical Alzheimer Disease and the Electronic Health Record: Balancing Confidentiality and Care
por: Gale, Seth A., et al.
Publicado: (2022)

Recruitment and retention of participant and study partner dyads in two multinational Alzheimer’s disease registration trials
por: Bernstein, Olivia M., et al.
Publicado: (2021)

Advances in Alzheimer's imaging are changing the experience of Alzheimer's disease
por: Stites, Shana D., et al.
Publicado: (2018)

Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial
por: Raman, Rema, et al.
Publicado: (2021)

Response to “Avoiding Methodological Bias in Studies of Amyloid Imaging Results Disclosure”
por: Grill, Joshua D., et al.
Publicado: (2019)

Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD)
por: Walter, S., et al.
Publicado: (2020)

Should persons with autosomal dominant AD be included in clinical trials?
por: Grill, Joshua D, et al.
Publicado: (2011)

Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing
por: Ketchum, Fred B., et al.
Publicado: (2022)

APP mouse models for Alzheimer's disease preclinical studies
por: Sasaguri, Hiroki, et al.
Publicado: (2017)

Clinical and Preclinical Studies of Fermented Foods and Their Effects on Alzheimer’s Disease
por: Kumar, Muganti Rajah, et al.
Publicado: (2022)

Effects of Self-Identification as a Caregiver on Expectations of Public Stigma of Alzheimer’s Disease
por: Stites, Shana D., et al.
Publicado: (2021)

THE ROLE OF CARE PARTNERS IN SUPPORTING INNER STRENGTH OF PERSONS NEWLY DIAGNOSED WITH MILD COGNITIVE IMPAIRMENT
por: Morgan, Brianna, et al.
Publicado: (2022)

Recruitment across two decades of NIH-funded Alzheimer’s disease clinical trials
por: Ritchie, Marina, et al.
Publicado: (2023)

How Biomarker-Based Diagnosis and Treatment Affect Alzheimer’s Stigma: Results of a Randomized Trial
por: Stites, Shana, et al.
Publicado: (2021)

Preclinical diagnosis of Alzheimer’s disease: Prevention or prediction?
por: Nitrini, Ricardo
Publicado: (2010)

‘That would be dreadful’: The ethical, legal, and social challenges of sharing your Alzheimer’s disease biomarker and genetic testing results with others
por: Largent, Emily A, et al.
Publicado: (2021)

Estimating attrition in mild-to-moderate Alzheimer’s disease and mild cognitive impairment clinical trials
por: Ritchie, Marina, et al.
Publicado: (2023)

Accelerating drug discovery for Alzheimer's disease: best practices for preclinical animal studies
por: Shineman, Diana W, et al.
Publicado: (2011)

APOE ε4, an Alzheimer’s disease susceptibility allele, and smoking cessation
por: Ashare, Rebecca L., et al.
Publicado: (2012)

Memory Awareness Influences Everyday Decision Making Capacity about Medication Management in Alzheimer's Disease
por: Cosentino, Stephanie, et al.
Publicado: (2011)

Precipitating Mechanisms of Falls in Preclinical Alzheimer’s Disease
por: Keleman, Audrey A., et al.
Publicado: (2023)

Quercetin in Animal Models of Alzheimer’s Disease: A Systematic Review of Preclinical Studies
por: Zhang, Xiao-Wen, et al.
Publicado: (2020)

Therapeutic Potential of Microbiota Modulation in Alzheimer’s Disease: A Review of Preclinical Studies
por: Benichou Haziot, Carla, et al.
Publicado: (2023)

Are Parkinson’s Disease Patients the Ideal Preclinical Population for Alzheimer’s Disease Therapeutics?
por: Tropea, Thomas F., et al.
Publicado: (2021)

Antiseizure Medications in Alzheimer’s Disease from Preclinical to Clinical Evidence
por: Bosco, Francesca, et al.
Publicado: (2023)

Should development of Alzheimer’s disease-specific intravenous immunoglobulin be considered?
por: Loeffler, David A
Publicado: (2014)

Natural Compounds for Alzheimer’s Disease Therapy: A Systematic Review of Preclinical and Clinical Studies
por: Andrade, Stephanie, et al.
Publicado: (2019)

The Value of OCT and OCTA as Potential Biomarkers for Preclinical Alzheimer’s Disease: A Review Study
por: López-Cuenca, Inés, et al.
Publicado: (2021)

Ferulic Acid in Animal Models of Alzheimer’s Disease: A Systematic Review of Preclinical Studies
por: Wang, Er-Jin, et al.
Publicado: (2021)

Attitudes toward clinical trials across the Alzheimer’s disease spectrum
por: Nuño, Michelle M., et al.
Publicado: (2017)

Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies
por: Sinsky, Jakub, et al.
Publicado: (2021)

Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease
por: Wang, Xiaoqi, et al.
Publicado: (2020)

Alzheimer’s Disease and Diabetes: Role of Diet, Microbiota and Inflammation in Preclinical Models
por: Carranza-Naval, Maria Jose, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_aoo2jqj0eudhbernvhde3uh9br